Depression

Discuss depression care challenges, comorbidities, and new treatments—submit cases, research, or CME ideas for Psychiatric Times’ September 2026 series.

Learn how clinicians tailor simple, measurable activity plans that boost depression and anxiety treatment—and improve long‑term adherence.

Meta-analysis finds intranasal esketamine boosts remission in MDD and TRD fast, but side effects and short trials leave long-term questions.

Post hoc SUSTAIN-1 data reveal who relapses after stopping intranasal esketamine in TRD—key risk factors guide personalized relapse-prevention plans.

Massive Lancet meta-analysis suggests most use of antidepressants while pregnant does not raise autism or ADHD risk after confounders, easing treatment decisions.

Anti-inflammatory drugs ease anhedonia and depressive symptoms in high-CRP depression, spotlighting CRP-guided treatment and lifestyle strategies while calling for stronger RCTs.

A multicenter study tests SAINT TMS for postpartum depression.

The triple-blinded EPISODE trial with active placebo and 4 dosing regimens yielded mixed results, reflecting the challenge of discerning psilocybin effect and distinguishing between enlightenment and expectation.

New US patent backs Denovo’s ANK3 biomarker guiding DB104 for treatment‑resistant depression, highlighting promising efficacy in selected patients.

Lifestyle medicine pillars help reshape depression and anxiety treatment in psychiatry.

FDA accelerates psychedelic drug development to advance agents for TRD, PTSD, and AUD.

In this CME article, learn how depression hides in organ failure, transplants, neurologic disease, and hormonal shifts—plus screening tips and safer treatment choices.

Psychiatry experts explain why off-label psych meds and polypharmacy can be essential.